Chronic exposure of interleukin-13 suppress the induction of matrix metalloproteinase-1 by tumour necrosis factor α in normal and scleroderma dermal fibroblasts through protein kinase B/Akt
- 2 October 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 191 (1), 84-95
- https://doi.org/10.1111/cei.13045
Abstract
Peripheral blood mononuclear cells taken from patients with scleroderma express increased levels of interleukin (IL)-13. Moreover, the expression of matrix metalloproteinase-1 (MMP-1) from involved scleroderma skin fibroblasts is refractory to stimulation by tumour necrosis factor (TNF)-α. To elucidate the mechanism(s) involved, we examined the effect of IL-13 on TNF-α-induced MMP-1 expression in normal and scleroderma human dermal fibroblast lines and studied the involvement of serine/threonine kinase B/protein kinase B (Akt) in this response. Dermal fibroblast lines were stimulated with TNF-α in the presence of varying concentrations of IL-13. Total Akt and pAkt were quantitated using Western blot analyses. Fibroblasts were treated with or without Akt inhibitor VIII in the presence of IL-13 followed by TNF-α stimulation. MMP-1 expression was analysed by real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using analysis of variance (anova) or Student's t-test. Upon TNF-α stimulation, normal dermal fibroblasts secrete more MMP-1 than systemic sclerosis (SSc) fibroblasts. This increase in MMP-1 is lost when fibroblasts are co-incubated with IL-13 and TNF-α. IL-13 induced a significant increase in levels of pAkt in dermal fibroblasts, while Akt inhibitor VIII reversed the suppressive effects of IL-13 on the response of cultured fibroblasts to TNF-α, increasing their expression of MMP-1. We show that IL-13 suppresses MMP-1 in TNF-α-stimulated normal and scleroderma dermal fibroblast. Akt inhibitor VIII is able to reverse the suppressive effect of IL-13 on MMP-1 expression and protein synthesis. Our data suggest that IL-13 regulates MMP-1 expression in response to TNF-α through an Akt-mediated pathway and may play a role in fibrotic diseases such as scleroderma.Funding Information
- Arthritis Foundation
- Scleroderma Foundation
- Le Bonheur Children's Research Center
- US Public Health Service/National Institutes of Health (AR-007317-29)
- VA Merit Award
This publication has 57 references indexed in Scilit:
- Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factorsAnnals Of The Rheumatic Diseases, 2012
- Periostin Facilitates Skin Sclerosis via PI3K/Akt Dependent Mechanism in a Mouse Model of SclerodermaPLOS ONE, 2012
- Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblastsClinical Rheumatology, 2012
- Akt inhibition up‐regulates MMP1 through a CCN2‐dependent pathway in human dermal fibroblastsExperimental Dermatology, 2010
- Role of a Novel PH-Kinase Domain Interface in PKB/Akt Regulation: Structural Mechanism for Allosteric InhibitionPLoS Biology, 2009
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Interleukin-13 Stimulates the Transcription of the Human α2(I) Collagen Gene in Human Dermal FibroblastsOnline Journal of Public Health Informatics, 2004
- Effects of Th2 Cytokines on Expression of Collagen, MMP-1, and TIMP-1 in Conjunctival FibroblastsInvestigative Ophthalmology & Visual Science, 2003
- Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cellsImmunology Today, 1994
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993